• Publications
  • Influence
Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial).
TLDR
Across dose ranges, rosuvastatin reduced total cholesterol significantly more than all comparators and triglycerides significantly more (p <0.001) than simvastsatin and pravastatin. Expand
National lipid association recommendations for patient-centered management of dyslipidemia: part 1--full report.
TLDR
This document provides support for a consensus set of recommendations for patient-centered management of dyslipidemia in clinical medicine and an elevated level of cholesterol carried by circulating apolipoprotein B-containing lipoproteins is a root cause of atherosclerosis. Expand
National Lipid Association recommendations for patient-centered management of dyslipidemia: part 1 - executive summary.
TLDR
The current Executive Summary highlights the major conclusions in Part 1 of the recommendations report of the NLA Expert Panel, which includes screening and classification of lipoprotein lipid levels in adults and targets for intervention in dyslipidemia management. Expand
National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 2.
TLDR
This document represents a continuation of the National Lipid Association recommendations developed by a diverse panel of experts who examined the evidence base and provided recommendations regarding the following topics: lifestyle therapies and strategies to improve patient outcomes by increasing adherence and using team-based collaborative care. Expand
Adiponectin, inflammation, and the expression of the metabolic syndrome in obese individuals: the impact of rapid weight loss through caloric restriction.
TLDR
Increases in plasma levels of adiponectin or reductions in TNF-alpha are not required for marked improvements in glucose/insulin and lipid metabolism with acute weight loss, and there was marked improvement in glucose, insulin, leptin, and triglycerides after 4-6 wk of weight loss. Expand
Consensus panel recommendation for incorporating lipoprotein-associated phospholipase A2 testing into cardiovascular disease risk assessment guidelines.
TLDR
Elevated Lp-PLA(2) levels should prompt consideration of increasing the cardiovascular risk category from moderate to high or high to very high risk, respectively, as a highly specific biomarker for vascular inflammation. Expand
Comparative effects on lipid levels of combination therapy with a statin and extended-release niacin or ezetimibe versus a statin alone (the COMPELL study).
TLDR
Low to moderate dose combination therapy with a statin and niacin ER provided broad control of lipids and lipoproteins independently associated with CHD, and Statin/niacin ER combination regimens also increased HDL-C and large HDL (HDL2) and lowered triglycerides andlipoprotein significantly more than other regimens. Expand
Effects of Statins on High-Density Lipoproteins: A Potential Contribution to Cardiovascular Benefit
TLDR
Statins cause modest increases in HDL-C and apo A-I probably mediated by reductions in CETP activity, plausible that such changes independently contribute to the cardiovascular benefits of the statin class but more studies are needed to further explore this possibility. Expand
Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trial
TLDR
Analysis showed that more patients in the rosuvastatin 10- to 40-mg groups than in the comparator groups who were at high risk of coronary heart disease according to National Cholesterol Education Program Adult Treatment Panel (ATP) III, Joint European Societies, or Canadian guidelines achieved the LDL-C goals of <100 mg dl−1 (<2.6 mmol l−1). Expand
Review of the evidence for the clinical utility of lipoprotein-associated phospholipase A2 as a cardiovascular risk marker.
TLDR
Lp-PLA(2) should be viewed today as an important cardiovascular risk marker whose utility is as an adjunct to the major risk factors to adjust absolute risk status and thereby modify low-density lipoprotein cholesterol goals. Expand
...
1
2
3
4
5
...